Abstracts Archive - Page 1312 of 2425 - ACR Meeting Abstracts

Abstract Number: 1597 • 2017 ACR/ARHP Annual Meeting
Arthritis and Hydroxychloroquine Are Associated with Decreased Risk of Macrophage Activation Syndrome Among Adults Hospitalized with SLE
Kristin D'Silva¹, Ezra Cohen², David J. Kreps³, Mary Beth Son² and Karen H. Costenbader³, ¹Internal Medicine, Brigham and Women's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Macrophage activation syndrome (MAS) is an uncommon but potentially fatal complication of SLE. We conducted a case-control study comparing hospitalized adults with SLE with…
Abstract Number: 1598 • 2017 ACR/ARHP Annual Meeting
Shrinking Lung Syndrome in Systemic Lupus Erythematosus Patients: A Diagnosis We Should Suspect More Often
Didem Saygin¹, Chris Lau², Marco Lopez-Velazquez³ and Kristin B. Highland⁴, ¹Internal Medicine, Department of Internal Medicine, Cleveland Clinic, Cleveland, Cleveland, OH, ²Pulmonary and Critical Care, Cleveland Clinic, Cleveland, OH, ³Internal Medicine, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology.org, Cleveland Clinic, Cleveland, OH
Background/Purpose: Shrinking lung syndrome (SLS) is a rare pulmonary manifestation of systemic lupus erythematosus (SLE) characterized by dyspnea, pleuritic chest pain, restriction on pulmonary function…
Abstract Number: 1599 • 2017 ACR/ARHP Annual Meeting
GRADE-Based Recommendations for the Diagnosis and Monitoring of Systemic Lupus Erythematosus in Canada
Stephanie Keeling¹, Zainab Alabdurubalnabi², J. Antonio Avina-Zubieta³, Susan Barr⁴, Louise Bergeron⁵, Sasha Bernatsky⁶, Josiane Bourré-Tessier⁷, Ann E. Clarke⁸, Alexandra Baril-Dionne⁹, Jan Dutz², Stephanie Ensworth¹⁰, Aurore Fifi-Mah¹¹, Paul R. Fortin¹², Dafna D Gladman¹³, Derek Haaland¹⁴, John G. Hanly¹⁵, Linda T Hiraki¹⁶, Sara Hussein⁹, Kimberly Legault¹⁷, Deborah M. Levy¹⁶, Lily Lim¹⁸, Mark Matsos¹⁹, Emily McDonald²⁰, Jorge Medina-Rosas²¹, Jordi Pardo Pardo²², Christine A. Peschken²³, Christian Pineau²⁴, Janet E. Pope²⁵, Tamara Rader²⁶, Jennifer Reynolds², Earl Silverman¹⁶, Manon Suitner⁹, Konstantinos Tselios²⁷, Murray Urowitz²⁸, Zahi Touma²⁹, Evelyne Vinet³⁰ and Nancy Santesso¹⁷, ¹Department of Medicine, University of Alberta, Division of Rheumatology, Edmonton, AB, Canada, ²Medicine, University of British Columbia, Vancouver, BC, Canada, ³Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Medicine, University of Calgary, Calgary, AB, Canada, ⁵Canadian Arthritis Patient Alliance, Toronto, ON, Canada, ⁶Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷Rheumatology, University of Montreal, Montreal, QC, Canada, ⁸Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰University of British Columbia, Vancouver, BC, Canada, ¹¹University of Calgary, Calgary, AB, Canada, ¹²Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada, ¹³Centre for Prongosis Studies in The Rheumatic Diseases, Toronto Western Hospital, Krembil Research Institute, Toronto, ON, Canada, ¹⁴Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ¹⁵Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ¹⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁷McMaster University, Hamilton, ON, Canada, ¹⁸Hospital for Sick Children, Toronto, ON, Canada, ¹⁹Medicine, McMaster University, McMaster, ON, Canada, ²⁰Medicine, McGill University, Montreal, QC, Canada, ²¹Rheumatology, Universidad de la Sabana, Bogota, Colombia, ²²Centre for Practice Changing Research, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²³RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, ²⁴Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ²⁵Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ²⁶The Ottawa Hospital - General Campus, Trials Search Coordinator Knowledge Translation Specialist Cochrane Musculoskeletal Group Centre for Practice Changing Research, Ottawa, ON, Canada, ²⁷Medicine, University of Toronto, Toronto, ON, Canada, ²⁸Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²⁹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ³⁰Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: To develop GRADE-based recommendations for the diagnosis and monitoring of systemic lupus erythematosus patients in Canada.Methods: Recommendations were developed using the GRADE (Grading of…
Abstract Number: 1600 • 2017 ACR/ARHP Annual Meeting
Lupus Nephritis Is Associated with Increased Rates of Hospitalization for Adverse Events on a Glucocorticoid Toxicity Index and in-Hospital Mortality Compared with Non-Renal Lupus and Matched Controls: An Analysis of Insurance Claims Data
Katherine Belendiuk¹, Huong Trinh², Matthew Cascino¹, Leonard Dragone¹, Daniel Keebler¹, Jay Garg¹ and Paul Brunetta¹, ¹Genentech, Inc., South San Francisco, CA, ²Genentech, South San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is heterogeneous in its clinical prognosis and lupus nephritis (LN) is a major cause of morbidity and mortality among children…
Abstract Number: 1601 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Non-Adherence Is Associated with Higher Sledai Scores in a Predominantly Hispanic Population
Alexandra Perel-Winkler¹, Kayla Neville¹, James Miceli¹, Samantha Nguyen¹, Miya Okado¹, Laura Geraldino-Pardilla¹, Teja Kapoor¹, Jon T. Giles² and Anca Askanase¹, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Non-adherence to medication has been shown to impact mortality, morbidity, and health care utilization in SLE and ranges from 40-80% depending on the methods…
Abstract Number: 1602 • 2017 ACR/ARHP Annual Meeting
Fatigue in Systemic Lupus: The Role of Disease Activity and Its Mediators
Desiree R Azizoddin¹, Meenakshi Jolly², Joel A. Block³ and Perry M. Nicassio⁴, ¹Department of Medicine and Behavioral Sciences, Rush University, Chicago, IL, ²Rush, Chicago, IL, ³Division of Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Cousins Center for PNI, UCLA, LA, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that leads to a variety of negative health outcomes. Though treatment continues to advance, fatigue…
Abstract Number: 1603 • 2017 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State: Can We Relax the Definition and Still Achieve Low Risk of SLE-Related Damage?
Michelle Petri¹, Daniel Goldman² and Laurence S Magder³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Lupus low disease activity state (LLDAS) is a systemic lupus erythematosus (SLE) outcome measure that combines low disease activity and a 7.5 mg limit…
Abstract Number: 1604 • 2017 ACR/ARHP Annual Meeting
Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Michelle Petri¹, Daniel Goldman² and Laurence S Magder^3,4, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public Health, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Outcome measures that combine control of SLE activity and prednisone reduction are clinically relevant. A clinical goal in SLE is to reduce risk of…
Abstract Number: 1605 • 2017 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State Protects Against Most Subtypes of Organ Damage in SLE
Michelle Petri¹, Daniel Goldman² and Laurence S Magder³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: In SLE the most common types of organ damage are osteoporotic fractures and cataracts. Other types of organ damage, such as end stage renal…
Abstract Number: 1606 • 2017 ACR/ARHP Annual Meeting
Cancer in an SLE Inception Cohort: Smoking May out-Perform Tumor Markers As a Risk Predictor
Sasha Bernatsky¹, Murray Urowitz², John G Hanly³, Ann E. Clarke⁴, Marvin J. Fritzler⁵, Caroline Gordon⁶, Juanita Romero-Diaz⁷, Graciela S. Alarcón⁸, Sang-Cheol Bae⁹, Michelle Petri¹⁰, Joan T. Merrill¹¹, Daniel J. Wallace¹², Paul R. Fortin¹³, Dafna D Gladman¹⁴, David A. Isenberg¹⁵, Anisur Rahman¹⁶, Susan Manzi¹⁷, Ola Nived¹⁸, Gunnar K. Sturfelt¹⁹, Christine A. Peschken²⁰, Jorge Sanchez-Guerrero²¹, Guillermo Ruiz-Irastorza²², Cynthia Aranow²³, Ronald F van Vollenhoven²⁴, Asad Zoma²⁵, Kristján Steinsson²⁶, Munther A Khamashta²⁷, Ellen M. Ginzler²⁸, Anca Askanase²⁹, Kenneth C. Kalunian³⁰, Mary Anne Dooley³¹, S. Sam Lim³², Diane L. Kamen³³, Søren Jacobsen³⁴, Manuel Ramos-Casals³⁵, Murat Inanc³⁶, Jennifer LF Lee³⁷ and Rosalind Ramsey-Goldman³⁸, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing,, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ¹⁰Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA, ¹³Université Laval, CHU de Québec, Québec, QC, Canada, ¹⁴Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹⁶Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁷Medicine, Allegheny Health Network, Pittsburgh, PA, ¹⁸Department of Rheumatology, University Hospital, Lund, Sweden, ¹⁹Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ²⁰RR 149G, Univ of Manitoba, Winnipeg, MB, Canada, ²¹Division of Rheumatology, Toronto Western Hospital, Toronto, AB, Canada, ²²Biocruces Health Research Institute, Barakaldo, Spain, ²³Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ²⁴AMC, F4-214, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²⁵University of Glasgow, Glaskow, United Kingdom, ²⁶Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁷Lupus Research Unit, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, St Thomas' Hospital, London, United Kingdom, ²⁸Rheumatology, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ²⁹Rheumatology, Columbia University, New York, NY, ³⁰Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³¹UNC Kidney Centre, Chapel Hill, NC, ³²Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³⁵Hospital Clinic, Barcelona, Spain, ³⁶Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁷Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³⁸FSM, Northwestern University, Chicago, IL
Background/Purpose: We assessed incident cancers in a large inception SLE cohort, and examined demographic and clinical factors, including tumor-related autoantibodies against proliferating cell nuclear antigen…
Abstract Number: 1607 • 2017 ACR/ARHP Annual Meeting
Tumor-Related Autoantibodies and Cancers in SLE: A Case-Control Study from a Single Centre
Sasha Bernatsky¹, Ann E. Clarke², Joyce Rauch³, Christian Pineau⁴, Evelyne Vinet⁵ and Marvin J. Fritzler⁶, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁵Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁶Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Patients with systemic lupus (SLE) have altered cancer profiles compared to the general population, with a higher risk of some cancers (e.g. lymphoma) and…
Abstract Number: 1608 • 2017 ACR/ARHP Annual Meeting
Entheseal Involvement in Systemic Lupus Erythematosus: An Ultrasound Study
Andrea Di Matteo¹, Emilio Filippucci², Edoardo Cipolletta², Valentina Lato², Jana Hurnakova^3,4, Iulia Satulu⁵, Rossella De Angelis² and Walter Grassi², ¹Polytechnic University of Marche, Rheumatology Clinic, Jesi, Italy, ²Polytechnic University of Marche, Rheumatology Clinic, jesi, Italy, ³1st Faculty of Medicine, Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, ⁴University Hospital Motol, Department of Pediatric and Adult Rheumatology, Prague, Czech Republic, ⁵Rheumatology Department, Internal Medicine Clinic, Kalmar County Hospital, kalmar, Sweden
Background/Purpose: A recent study revealed ultrasound (US) findings indicative of entheseal involvement in a small group of patients with systemic lupus erytemathosus (SLE), raising the…
Abstract Number: 1609 • 2017 ACR/ARHP Annual Meeting
Telomere Length and Coronary Artery Atherosclerosis in Patients with Systemic Lupus Erythematosus
Nathan Stein¹, Joseph F. Solus¹, Annette M. Oeser¹, Paolo Raggi², C Michael Stein¹ and Michelle J. Ormseth³, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alberta, Edmonton, AB, Canada, ³Medicine, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Coronary atherosclerosis increases with age but is more prevalent in patients with systemic lupus erythematosus (SLE) independent of chronological age; this increased prevalence has…
Abstract Number: 1610 • 2017 ACR/ARHP Annual Meeting
The Impact of Alcohol Use on Cardiovascular Events and Overall Mortality in Women with Systemic Lupus Erythematosus
April Jorge¹, Leo Lu², Yuqing Zhang³, Sharan K. Rai⁴ and Hyon K. Choi⁴, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Women with SLE have an increased risk of cardiovascular disease (CVD) and premature death. In the general population, moderate alcohol intake is associated with…
Abstract Number: 1611 • 2017 ACR/ARHP Annual Meeting
Increased Body Mass Index May Not be a Risk Factor for the Development of Lupus Nephritis
Yu Pei Chock¹, Abhijeet Danve¹, Wei Fu² and Michelle Petri³, ¹Rheumatology, Yale University, New Haven, CT, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Studies have indicated that increased body mass index (BMI) is a risk factor for development of Chronic Kidney Disease (CKD). Obesity is a low…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].